1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Sotomi Y, Kozuma K, Higuchi Y, Nakazawa G, Morino Y, Ando K, Ako J, Tanabe K, Muramatsu T, Kobayashi K, Ichibori Y, Ishihara T, Hirooka K, Suwa S, Warisawa T, Naganuma T, Kikuchi A, Shutta R, Okamoto N, Tanabe Y, Okamura A, Kashiwabara K, Hikoso S, Sakata Y, OPTIMA-AF Investigators

Open source

DOI
10.1016/s0140-6736(26)00665-3
Published
2026 Aug 1
Container
Lancet (London, England)
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00665-3,
  title = {1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.},
  author = {Sotomi Y and Kozuma K and Higuchi Y and Nakazawa G and Morino Y and Ando K and Ako J and Tanabe K and Muramatsu T and Kobayashi K and Ichibori Y and Ishihara T and Hirooka K and Suwa S and Warisawa T and Naganuma T and Kikuchi A and Shutta R and Okamoto N and Tanabe Y and Okamura A and Kashiwabara K and Hikoso S and Sakata Y and OPTIMA-AF Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00665-3},
  url = {https://doi.org/10.1016/s0140-6736(26)00665-3}
}

RIS

TY  - JOUR
TI  - 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
AU  - Sotomi Y
AU  - Kozuma K
AU  - Higuchi Y
AU  - Nakazawa G
AU  - Morino Y
AU  - Ando K
AU  - Ako J
AU  - Tanabe K
AU  - Muramatsu T
AU  - Kobayashi K
AU  - Ichibori Y
AU  - Ishihara T
AU  - Hirooka K
AU  - Suwa S
AU  - Warisawa T
AU  - Naganuma T
AU  - Kikuchi A
AU  - Shutta R
AU  - Okamoto N
AU  - Tanabe Y
AU  - Okamura A
AU  - Kashiwabara K
AU  - Hikoso S
AU  - Sakata Y
AU  - OPTIMA-AF Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00665-3
UR  - https://doi.org/10.1016/s0140-6736(26)00665-3
ER  - 

APA

Y, S., K, K., Y, H., G, N., Y, M., K, A., J, A., K, T., T, M., K, K., Y, I., T, I., K, H., S, S., T, W., T, N., A, K., R, S., N, O., Y, T., A, O., K, K., S, H., Y, S., & Investigators, O. (2026). 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00665-3

Source records